Luke Halpern, Assistant Editor

The monoclonal antibody demonstrates the ability to reduce the incidence and improve symptoms related to sleep disorders and psychiatric disorders such as anxiety.

Factors associated with intravenous immunoglobulin (IVIG)-related adverse events include older age, dehydration, and administration of multiple IVIG infusions.

Currently available for prescription in the United States, vibegron is now the first and only β3 agonist FDA approved to treat patients living with OAB and being treated for BPH.

The approval of the generic to liraglutide injection, currently in shortage, could help increase patient access to the type 2 diabetes treatment.

Clinical trials will seek to evaluate the immunogenicity and safety of the LBT-SA7 vaccine.

The new approval continues to expand the therapeutic potential of GLP-1 medications such as tirzepatide, now being deemed effective in patients with obstructive sleep apnea.

Knowing which patients are at higher risk for developing urticaria by analyzing their history of food allergies could lead to better outcomes in this population.

Proven effective in the treatment of atopic dermatitis (AD) and other allergic conditions, these study results confirm the ability of dupilumab to improve symptoms in children with other concurrent conditions.

Firas El Chaer, MD, discusses newly-presented data at ASH demonstrating nuvisertib's effectiveness in myelofibrosis.

Abstract data presented in September demonstrate that the drug elicited strong antitumor activity in the second line in both platinum-sensitive and -resistant patients.

Often used as a treatment for severe exacerbations of myasthenia gravis, intravenous immunoglobulin can lead to high financial toxicity and resource utilization.

Based on positive results from the HERCULES trial, the new designation will allow for more thorough regulatory review and development of the multiple sclerosis treatment.

The approval builds on previous indications for tapinarof, an aryl hydrocarbon receptor agonist, for the topical treatment of atopic dermatitis.

Ira Zackon, MD, explains where future research lies regarding the implementation of bispecific antibodies in community oncology settings.

Sonja Zweegman, MD, PhD, explains the improvements in minimum residual disease negativity found after treatment with daratumumab and the VRd regimen in patients with newly-diagnosed multiple myeloma who are transplant-ineligible.

Luca Bertamini, MD highlights the potential clinical implications of using circulating tumor cells as a biomarker in patients with newly-diagnosed multiple myeloma.

Ira Zackon, MD explains his analysis of bispecific antibody utilizaton for relapsed or refractory multiple myeloma in community oncology centers.

Robert Rifkin, MD, FACP, discusses multiple abstracts featuring drugs demonstrating efficacy in patients with relapsed/refractory multiple myeloma.

Shirley D'Sa, MD, highlights the long-term efficacy and tolerability of zanubrutinib in patients with Waldenström macroglobulinemia, as seen in the long-term extension of ASPEN.

Amir Ali, PharmD, BCOP highlights the success of shorter-treatment duration venetoclax in patients with acute myeloid leukemia and efficacy of pre-transplant blinatumomab in those with acute lymphocytic leukemia.

Rakesh Popat, MBBS, PhD explains the mechanisms of action behind the improvement in minimum residual disease in patients with lenalidomide-refractory multiple myeloma with cilta-cel compared with standard of care.

Jason Wang, MD highlights the reduction in incidence and severity of adverse events such as cytokine release syndrome and ICANS following axi-cel treatment in patients with R/R LBCL.

Donald Moore discusses some of the obstacles that bispecific antibodies have faced in community cancer centers, including misconceptions coupled with a prevalent toxicity profile.

Jose Tinajero discusses how certain mutations can be indicators of blinatumomab treatment failure in patients with B-cell acute lymphoblastic leukemia.

Mazyar Shadman, MD, MPH, discusses the continued efficacy of zanubrutinib in patients with chronic lymphocytic leukemia.

Jerome Adams, former US surgeon general, discusses the importance of receiving recommended vaccines against influenza and COVID-19 for health care personnel.

Pharmacists must make time for self-care and ensure a proper balance of work and life among their staff and themselves, according to National Association of Boards of Pharmacy Executive Director Al Carter.

Prevalence increased across all subgroups among children and adolescents, with decreases observed in young adults and elderly populations.

The American Society of Hematology (ASH) Annual Meeting and Exposition will include the latest news and clinical trial updates in the hematology field.

The decline was attributed to continued adherence to infection prevention and control measures.